%0 Journal Article
%T Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition
%A Sriharsha Grevich
%A Susan Shenoi
%J Archive of "Adolescent Health, Medicine and Therapeutics".
%D 2017
%R 10.2147/AHMT.S109495
%X Systemic juvenile idiopathic arthritis (SJIA) is a disease marked with arthritis and several features of systemic inflammation including fevers, rashes, hepatosplenomegaly, lymphadenopathy, and serositis. The presentation can be variable and arthritis can be a later feature. Macrophage activation syndrome can be a life-threatening complication of this illness and requires early recognition and prompt therapy. Advancements in understanding the biology of SJIA have led to the development of cytokine-targeted therapies, mainly interleukin-1 (IL-1) and IL-6 inhibitors that have significantly improved outcomes. In this review, we provide an update on the advances in the understanding of SJIA biology and also the therapeutic options
%K systemic juvenile idiopathic arthritis
%K IL-1 inhibitors
%K IL-6 inhibitors
%K anakinra
%K tocilizumab
%K canakinumab
%K macrophage activation syndrome
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687245/